Breaking News

Galapagos, Roche End Fibrosis Alliance

March 8, 2013

Galapagos regains rights to all assays and targets

Galapagos NV and Roche have agreed to end their alliance in fibrosis. Galapagos will receive a payment of $7.5 million for work completed in 2012. Galapagos regains worldwide rights to all fibrosis assays and the targets discovered in the alliance. The company received a total of approximately $20.8 million in upfront and milestone payments from Roche under the collaboration.
 
"We regret that Roche ended the alliance due to a strategic change, but the good news is that all assets have returned to Galapagos," said Onno van de Stolpe, chief executive officer of Galapagos. "Our plan is to find another partner to continue the search for compounds against these debilitating diseases."

Related Contract Manufacturing:

blog comments powered by Disqus
  • Limiting APIs in Manufacturing Effluent

    Limiting APIs in Manufacturing Effluent

    Joan Tell, Robert Drinane, Bruce Naumann, Jessica Vestel, and Gregory Gagliano, Merck & Co., Inc.||June 2, 2016
    An approach for setting limits on pharmaceuticals discharged in manufacturing effluent

  • Successful Method Transfer of Solid Oral Dosage

    Successful Method Transfer of Solid Oral Dosage

    John Frankonis, Ropack Pharma Solutions||June 2, 2016
    The three steps outlined will help guide the process of completing a successful analytical method transfer

  • Who’s the Right Service Provider for You?

    Who’s the Right Service Provider for You?

    Raymond Peck, VxP Pharma Services||June 2, 2016
    Factors to consider when choosing between using one integrated CDMO or a series of smaller functional service providers